Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT02923739
Title Induction Discontinuation Trial of Emactuzumab Following Paclitaxel and Bevacizumab in Patients With Platinum-Resistant, Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer - REDIRECT
Recruitment Active, not recruiting
Gender female
Phase Phase II
Variant Requirements No
Sponsors M.D. Anderson Cancer Center
Indications

ovary epithelial cancer

fallopian tube cancer

peritoneum cancer

Therapies

Bevacizumab + Emactuzumab + Paclitaxel

Bevacizumab + Paclitaxel

Age Groups: senior | adult
Covered Countries USA

Facility Status City State Zip Country Details
MD Anderson Cancer Center at Cooper-Voorhees Voorhees New Jersey 08043 United States Details
University of Oklahoma Health Sciences Center Oklahoma City Oklahoma 73104 United States Details
UT Southwestern/Simmons Cancer Center-Dallas Dallas Texas 75390 United States Details
M D Anderson Cancer Center Houston Texas 77030 United States Details
The Woman's Hospital of Texas Houston Texas 77054 United States Details
MD Anderson Regional Care Center-Katy Houston Texas 77094 United States Details
MD Anderson Regional Care Center-Bay Area Nassau Bay Texas 77058 United States Details
MD Anderson Regional Care Center-Sugar Land Sugar Land Texas 77478 United States Details
MD Anderson Regional Care Center-The Woodlands The Woodlands Texas 77384 United States Details
*Shaded cells indicate that there was no data available from clincialtrials.gov for the field